STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 36,532 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 36,532 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average price of $15.49 per share, for a total transaction of $565,880.68. Following the completion of the purchase, the insider now owns 11,289,437 shares of the company’s stock, valued at approximately $174,873,379.13. This represents a 0.32 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The shares were bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were bought at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The shares were bought at an average price of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The shares were bought at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The shares were bought at an average price of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Trading Down 3.8 %

Shares of STAA opened at $15.35 on Friday. The business’s 50-day moving average price is $23.37 and its 200 day moving average price is $28.97. The stock has a market capitalization of $756.45 million, a P/E ratio of 34.89 and a beta of 0.62. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors have recently bought and sold shares of the stock. Van ECK Associates Corp grew its holdings in shares of STAAR Surgical by 12.7% during the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 393 shares in the last quarter. Creative Planning grew its holdings in shares of STAAR Surgical by 8.0% during the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 408 shares in the last quarter. LMR Partners LLP grew its holdings in shares of STAAR Surgical by 2.2% during the 3rd quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock valued at $1,290,000 after acquiring an additional 743 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of STAAR Surgical during the 3rd quarter valued at $37,000. Finally, Quarry LP purchased a new position in shares of STAAR Surgical during the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on STAA. Stephens reaffirmed an “equal weight” rating and set a $28.00 target price on shares of STAAR Surgical in a report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Wednesday. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday. StockNews.com lowered STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday. Finally, BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $26.86.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.